Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
ERJ Open Research 2022 8: 00239-2022; DOI: 10.1183/23120541.00239-2022
Rolof G.P. Gijtenbeek
1Dept of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rolof G.P. Gijtenbeek
Vincent van der Noort
2Dept of Biometrics, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincent van der Noort
Joachim G.J.V. Aerts
3Dept of Pulmonary Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeske A. Staal-van den Brekel
4Dept of Respiratory Medicine, Hospital Group Twente, Almelo/Hengelo, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Egbert F. Smit
5Dept of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Egbert F. Smit
Frans H. Krouwels
6Dept of Respiratory Medicine, Spaarne Hospital, Hoofddorp, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank A. Wilschut
7Dept of Respiratory Medicine, Gelderse Vallei Hospital, Ede, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Jeroen N. Hiltermann
8Dept of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for T. Jeroen N. Hiltermann
Wim Timens
9Dept of Pathology and Medical Biology, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wim Timens
Ed Schuuring
9Dept of Pathology and Medical Biology, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joost D.J. Janssen
10Dept of Respiratory Medicine, Máxima Medical Centre, Eindhoven/Veldhoven, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martijn Goosens
11Dept of Pulmonary Medicine, Gelre Hospitals, Zutphen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul M. van den Berg
12Dept of Respiratory Medicine, Maasstad Hospital, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Joop de Langen
13Dept of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jos A. Stigt
14Dept of Respiratory Medicine, Isala Hospital, Zwolle, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben E.E.M. van den Borne
15Dept of Pulmonary Diseases, Catharina Hospital, Eindhoven, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry J.M. Groen
8Dept of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wouter H. van Geffen
1Dept of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wouter H. van Geffen
  • For correspondence: wouter.van.geffen@mcl.nl
Anthonie J. van der Wekken
8Dept of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, Groningen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    a) Progression-free survival and b) overall survival in months by treatment arm. Data are presented with 95% CI. CPE: cisplatin-pemetrexed-erlotinib; E: erlotinib; HR: hazard ratio; cor: corrected.

Tables

  • Figures
  • Supplementary Materials
  • TABLE 1

    Baseline patient characteristics

    CPEErlotinib monotherapyAll
    Patients111122
    Age, years60 (58–64)67 (62–68)64 (59–68)
    Males5 (45)5 (45)10 (45)
    Performance score
     08 (73)7 (64)15 (68)
     13 (27)4 (36)7 (32)
    Smoking
     Never-smoker6 (55)2 (18)8 (36)
     Former smoker5 (45)5 (45)10 (45)
     Current smoker0 (0)4 (36)4 (18)
     Pack-years14 (9–15)14 (6–19)14 (7–18)
    Stage IV11 (100)11 (100)22 (100)
    Nonsquamous11 (100)11 (100)22 (100)
    Type of EGFR mutation
     Exon 19 deletion7 (64)7 (64)14 (64)
     L858R2 (18)3 (27)5 (23)
     Other2 (18)1 (9)3 (13)

    Data are presented as n, median (interquartile range) or n (%). CPE: cisplatin-pemetrexed-erlotinib; EGFR: epidermal growth factor receptor.

    • TABLE 2

      Outcome measures by treatment arm

      CPEErlotinib monotherapyHR (95% CI)
      Patients randomised1111
      PFS months, median (95% CI)13.7 (5.2–18.8)10.3 (7.1–15.5)0.62 (0.25–1.57)#
      Overall survival, median (95% CI)31.7 (21.8–61.9)17.2 (11.5–45.5)0.55 (0.22–1.41)
      1-year overall survival, % (95% CI)100 (72–100)
      ORR, % (95% CI)64 (31–89)55 (23–83)
       Complete response1 (9)1 (9)
       Partial response6 (54)5 (46)
       Stable disease4 (36)5 (46)
      Duration of response in months, median (95% CI)10.8 (7.3–31.2)8.0 (5.5–8.7)0.43 (0.12–1.47)

      Data are presented as n or n (%), unless otherwise stated. CPE: cisplatin-pemetrexed-erlotinib; HR: hazard ratio; PFS: progression-free survival; ORR: overall response rate. #: after compensating for numbers of days receiving erlotinib HR 0.24, 95% CI 0.07–0.83; p=0.02.

      • TABLE 3

        Number of treatment-related adverse events with incidence ≥10% or grade ≥3

        All gradesGrade ≥3#
        CPEE monotherapyp-valueCPEE
        Abdominal pain1100
        Alopecia200.4800
        Anaemia1000
        Anorexia600.0110
        Diarrhoea310.5910
        Dry eyes0100
        Dry skin541.0000
        Fatigue520.3610
        Hypocalcaemia1010
        Hypomagnesaemia1010
        Mucositis1010
        Nail infection160.0600
        Nausea2110
        Neutropenia1010
        Pruritus1101
        Rash680.6610
        Renal toxicity300.2120
        Weight loss200.4800

        CPE: cisplatin-pemetrexed-erlotinib; E: erlotinib. #: due to limited sample size, no statistical analysis was performed for events grade ≥3.

        Supplementary Materials

        • Figures
        • Tables
        • Supplementary Material

          Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

          Supplementary material 00239-2022.SUPPLEMENT

        PreviousNext
        Back to top
        Vol 8 Issue 4 Table of Contents
        ERJ Open Research: 8 (4)
        • Table of Contents
        • Index by author
        Email

        Thank you for your interest in spreading the word on European Respiratory Society .

        NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

        Enter multiple addresses on separate lines or separate them with commas.
        Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
        (Your Name) has sent you a message from European Respiratory Society
        (Your Name) thought you would like to see the European Respiratory Society web site.
        CAPTCHA
        This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
        Print
        Citation Tools
        Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
        Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
        ERJ Open Research Oct 2022, 8 (4) 00239-2022; DOI: 10.1183/23120541.00239-2022

        Citation Manager Formats

        • BibTeX
        • Bookends
        • EasyBib
        • EndNote (tagged)
        • EndNote 8 (xml)
        • Medlars
        • Mendeley
        • Papers
        • RefWorks Tagged
        • Ref Manager
        • RIS
        • Zotero
        Share
        Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
        Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
        ERJ Open Research Oct 2022, 8 (4) 00239-2022; DOI: 10.1183/23120541.00239-2022
        del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
        Full Text (PDF)

        Jump To

        • Article
          • Abstract
          • Abstract
          • Introduction
          • Material and methods
          • Results
          • Discussion
          • Supplementary material
          • Footnotes
          • References
        • Figures & Data
        • Info & Metrics
        • PDF

        Subjects

        • Lung cancer
        • Pulmonary pharmacology and therapeutics
        • Tweet Widget
        • Facebook Like
        • Google Plus One

        More in this TOC Section

        Original research articles

        • Bacterial DNA amplifies neutrophilic inflammation in IL-17-exposed airways
        • PERSPIRE: a cohort study
        • Ipratropium bromide in EILO
        Show more Original research articles

        Thoracic tumours

        • Treatment initiation and survival in lung cancer
        • FV and IRAE severity in advanced cancer patients on ICIs
        Show more Thoracic tumours

        Related Articles

        Navigate

        • Home
        • Current issue
        • Archive

        About ERJ Open Research

        • Editorial board
        • Journal information
        • Press
        • Permissions and reprints
        • Advertising

        The European Respiratory Society

        • Society home
        • myERS
        • Privacy policy
        • Accessibility

        ERS publications

        • European Respiratory Journal
        • ERJ Open Research
        • European Respiratory Review
        • Breathe
        • ERS books online
        • ERS Bookshop

        Help

        • Feedback

        For authors

        • Instructions for authors
        • Publication ethics and malpractice
        • Submit a manuscript

        For readers

        • Alerts
        • Subjects
        • RSS

        Subscriptions

        • Accessing the ERS publications

        Contact us

        European Respiratory Society
        442 Glossop Road
        Sheffield S10 2PX
        United Kingdom
        Tel: +44 114 2672860
        Email: journals@ersnet.org

        ISSN

        Online ISSN: 2312-0541

        Copyright © 2023 by the European Respiratory Society